What "Naked" Botulinum Toxin Means
Xeomin contains only the 150-kDa botulinum toxin A protein, stripped of the complexing proteins present in Botox (900 kDa) and Dysport (500 kDa). The theory behind this design is twofold: reduced immunogenicity (lower risk of antibody formation against the toxin itself) and potentially more predictable diffusion due to the absence of protein bulk.
In practice, the clinical significance of the "naked" formulation remains debated. Some practitioners report that Xeomin diffuses more readily than Botox, requiring more precise injection technique to avoid unwanted spread. Others find the difference negligible. The real advantage for some practices lies in the immunogenicity angle—patients who have developed neutralizing antibodies to Botox or Dysport may respond to Xeomin, though cross-reactivity can still occur.
FDA-Approved Indications
Xeomin is cleared for:
- Glabellar lines (frown lines)
- Forehead lines
- Crow's feet (lateral canthal lines)
These indications cover the standard aesthetic trifecta. The approval pathway was a 510(k) submission, not a full PMA, which is typical for botulinum toxin products once the class was established by Botox.
Dosing and Unit Equivalency
Xeomin is dosed in units, but the unit-to-unit equivalency with Botox and Dysport is not 1:1. Most practitioners and the literature treat Xeomin units as approximately equivalent to Botox units on a 1:1 basis for practical dosing, though some data suggest Xeomin may require slightly higher volumes to achieve identical results. Verify current dosing guidance with your supplier and training materials, as formulation science continues to evolve.
Market Position and Supply
Revance has aggressively pursued market share through the Evolus Rewards loyalty program (formerly Revance Rewards), offering rebates and volume incentives competitive with Allergan's Alle and Galderma's Aspire programs. Xeomin pricing per unit is typically competitive with or slightly below Botox, making it an economically rational choice for practices seeking margin optimization or patient differentiation.
The "naked" positioning has also resonated with a subset of aesthetic consumers who perceive it as a purer or more refined product, though this is largely marketing narrative rather than clinically validated superiority.
Regulatory Status Summary
Xeomin remains fully approved and actively marketed. There are no pending regulatory actions or safety signals that would affect its status. Like all botulinum toxin products, it carries a black-box warning regarding the risk of toxin spread beyond the injection site, though serious adverse events remain rare at standard aesthetic doses.
For practice owners, Xeomin represents a legitimate third option in the neuromodulator market—useful for patients with prior antibody formation, as a margin-play alternative to Botox, or simply as a clinical differentiator in a competitive market.
Frequently asked questions
Is Xeomin FDA approved for cosmetic use?
Yes, Xeomin received FDA clearance in 2010 for glabellar lines and has since expanded to include forehead lines and crow's feet. It is manufactured by Revance Therapeutics and is fully approved and actively marketed in the U.S.
What does 'naked' botulinum toxin mean and does it matter?
Xeomin contains only the 150-kDa botulinum toxin protein without the complexing proteins found in Botox (900 kDa) or Dysport (500 kDa). The theory is reduced immunogenicity and more predictable diffusion, though clinical significance remains debated—some practitioners report more precise injection is needed to avoid unwanted spread.
Can Xeomin work for patients who are resistant to Botox?
Xeomin may work for patients who have developed neutralizing antibodies to Botox or Dysport because it lacks the accessory proteins those formulations contain. However, cross-reactivity can still occur, so results are not guaranteed.
What is the unit-to-unit dosing equivalency between Xeomin and Botox?
Most practitioners treat Xeomin units as approximately 1:1 equivalent to Botox units for practical dosing purposes, though some data suggest Xeomin may require slightly higher volumes to achieve identical results. Always verify current dosing guidance with your supplier.
How does Xeomin pricing compare to Botox and Dysport?
Xeomin pricing per unit is typically competitive with or slightly below Botox. Revance offers the Evolus Rewards loyalty program with rebates and volume incentives comparable to Allergan's Alle and Galderma's Aspire programs, making it economically attractive for margin optimization.
What are the FDA-approved indications for Xeomin?
Xeomin is cleared for glabellar lines (frown lines), forehead lines, and crow's feet (lateral canthal lines). These three indications cover the standard aesthetic treatment areas for neuromodulators.
